Icon Plc ADR ICLR
-
ICON Sees Sequential Improvement in 1Q; We Expect Earnings To Accelerate Throughout 2012
ICON's ICLR first-quarter results were evidence of the ongoing recovery in the company’s operations and within the contract research industry …
-
Our Outlook for Health-Care Stocks
… Medium 0.71 Roche $52.00 Wide Medium 0.83 WellPoint $105.00 Narrow Medium 0.64 Data as of 03-23-12. Icon PLC ICLR ICON's growing scale has helped it gain entrance into the upper echelon of the contract research industry, and we think the …
-
ICON ( ICLR ): Q4 EPS of $0.07 misses by $0.01. Revenue of $243M (+4.7% Y/Y) misses by $8M. (PR)
ICON ( ICLR ): Q4 EPS of $0.07 misses by $0.01 . Revenue of $243M (+4.7% Y/Y) misses by $8M . ( PR ) Post your comment!
-
ICON Falls Shy of Our EPS Estimate in 4Q, But Earnings Set to Double in 2012
ICON ICLR reported fourth-quarter results that caused the firm to fall slightly shy of our full-year expectations. However, as much …
-
CROs Will Return to Relevance in 2012
… which require substantial new costs without an immediate increase in compensating revenue, have weighed on earnings for ICON ICLR and Parexel PRXL--which were named the two strategic partners of Pfizer PFE in May. Although price concessions accompany …
-
Option Spotlight: Keep Your Portfolio Healthy With These Health-Care Picks
… competitive advantages than any pharmacy benefit manager in history." C l ick here for option prices on Express Scripts. Icon Plc. ICLR is a growing player in the field of contract testing for large pharmaceutical companies. Icon takes care of the myriad details …
-
ICON's Earnings Slide in Third Quarter, But Record Demand Positions Firm for Near-Term Rebound
As expected, ICON ICLR continued to see its earnings slide during the third quarter. We already have factored near-term profitability pressure into …
-
ICON plc ([[ ICLR ]] -0.2%) lags the general market after JPMorgan cut the shares to neutral over concerns that near-term expenses from the company's partnerships will cut into margins.
ICON plc ( ICLR -0.2% ) lags the general market after JP Morgan cut the shares to neutral over concerns that near-term expenses from the company's partnerships will cut into margins. Post your comment!
-
Leading CROs Will Gain From Drug Research Rebound
By Morningstar : We think the contract research organization (CRO) industry has turned a corner, as evidenced by a resurgence in new business activity and revenue growth over the past few quarters. The second quarter marked the first period since the beginning of the drug-development slowdown that
-
Opportunities In Foreign Healthcare Equipment And Services Provider Stocks
… China 3 Concord Medical Services CCM China 4 Edap EDAP France 5 Fresenius Medical Care FMS Germany 6 Grifols GRFS Spain 7 ICON ICLR Ireland 8 Mindray Medical International MR China 9 Smith & Nephew SNN United Kingdom 10 Trinity Biotech TRB Ireland Complete …